United States (Change Country)TW-37 Chemical Structure
TW-37 is a Bcl-2 protein family inhibitor with a Ki of 0.29 μM. TW-37 binds to the BH3 binding groove in Bcl-2 protein competing with BH3 peptides derived from Bid, Bim, and Bad proteins. TW-37 binds to Bcl-2 with a Ki value of 290 nM and also to Bcl-xL and Mcl-1 with high affinities. TW-37 potently inhibits cell growth in PC-3 prostate cancer cells with an IC50 value of 200 nM and effectively induces apoptosis in a dose-dependent manner. TW-37 has an IC50 of 1.1 μM for primary human endothelial cells and averaged 0.3 μM for head and neck cancer cells (OSCC3, UM-SCC-1, and UMSCC-74A). The combination of TW-37 and cisplatin showed enhanced cytotoxic effects for endothelial cells and HNSCC in vitro, compared with single agent treatment. [1][2]
[1] Cancer Res 2006;66:8698-8706
[2] Mol Cancer Ther 2009;8:893-903
| Molecular Weight (WM): | 573.7 |
|---|---|
| Formula: | C33H35NO6S |
| Solubility(R.T.:25°C): | DMSO 115mg/mL |
| Water <1mg/mL | |
| Ethanol 4mg/mL |
A collection of 729 inhibitors
A collection of 277 kinase inhibitors
A collection of 789 FDA approved drugs
A collection of 146 natural products
A collection of 84 chemotherapeutic agents
A collection of 1484 bioactive compounds
A collection of 118 tyrosine kinase inhibitors
;Cell Death Differ, 2012, 19(12), 1896-907 TW-37 purchased from Selleck
;Dr. Christine Hawkins of La Trobe University TW-37 purchased from Selleck
;Dr. Zhang of Tianjin Medical University TW-37 purchased from Selleck
Keywords:buy TW-37 | TW-37 supplier | purchase TW-37 | TW-37 cost | TW-37 manufacturer | order TW-37 | TW-37 distributor